Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01100658 · ClinicalTrials.gov registry record · NA

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

A NA study, sponsored by University of Minnesota.

Terminated
Registry status
NA
Development phase
1
Enrollment target

NCT01100658: Clinical Trial NA study, sponsored by University of Minnesota.

NCT01100658 is a NA study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01100658, a NA study, was terminated before completion, sponsored by University of Minnesota.

TERMINATED
Registry status
NA
Development phase
1 participants
Enrollment target

Study Summary

While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.

Primary Outcome

Child performance on neuropsychological testing (i.e., using Test of Variables of Attention \[TOVA\] which is a computerized test of attention that assists in the screening, diagnosis, and treatment monitoring of attention disorders, like Attention Deficit Hyperactivity Disorder \[ADHD\], and working memory index of the WisSC IV. Standard scores average = 100 +/- 15. Higher scores indicate better performance. Scores \< or = 1 SD below the mean represent area of deficit.

Interventions

  • DRUG Placebo
  • DRUG Methylphenidate

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2010-05
Est. Completion 2010-11
Phase NA
University of Minnesota

966 total trials

Why NCT01100658 stopped before completion

NCT01100658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01100658 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01100658 about?

NCT01100658 is a clinical study titled "Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors". While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness ...

What is the current status of trial NCT01100658?

This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2010-05. Estimated completion is 2010-11.

What interventions are being tested in trial NCT01100658?

The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG).

Who is sponsoring clinical trial NCT01100658?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01100658's enrollment target sits among peer trials

1 2001st of 2000 the lowest of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01100658, the US trial registry maintained by the National Library of Medicine. NCT01100658 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.